InMed Pharmaceuticals Inc. operates as a clinical-stage pharmaceutical firm, concentrating its efforts on the investigation and creation of therapeutic solutions derived from cannabinoids. Its primary product, INM-755, is a cannabinol-infused topical cream that is currently progressing through its second Phase I clinical trial for the management of epidermolysis bullosa. Beyond this lead candidate, the company is also developing INM-088, which is undergoing preclinical studies for glaucoma treatment, and INM-405, intended for pain relief. Its broader development pipeline encompasses…
Consensus price target: $20.00 (+51.4% upside from $13.21)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC 10 percent owner | Oct 19, 2026 | Purchase | 1,086 | $1.43K |
| ADAR1 Capital Management, LLC 10 percent owner | Oct 15, 2026 | Purchase | 984 | $1.3K |
| ADAR1 Capital Management, LLC 10 percent owner | Oct 14, 2026 | Purchase | 8,021 | $10.67K |
| ADAR1 Capital Management, LLC 10 percent owner | Oct 13, 2026 | Purchase | 564 | $750.12 |
| ADAR1 Capital Management, LLC 10 percent owner | Oct 8, 2026 | Purchase | 2,256 | $3K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2026 | $3.18B | +64167.28% | $-12.56M |
| 2025 | $4.94M | +7.5% | $-8.16M |
| 2024 | $4.6M | +11.18% | $-7.68M |
Stock data for INM: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics